MLX

Max-like protein X

638 patent compounds predicted against MLX, 284 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13393698	0.77	1/20
SCHEMBL13393918	0.77	1/20
SCHEMBL10207177	0.73	1/20
SCHEMBL14144736	0.61	1/20
SCHEMBL13380037	0.56	1/20
SCHEMBL13393683	0.56	1/20
SCHEMBL13393704	0.56	1/20
SCHEMBL12105450	0.56	1/20
SCHEMBL13380061	0.56	1/20
SCHEMBL13393695	0.56	1/20
SCHEMBL13393832	0.56	1/20
SCHEMBL13393860	0.56	1/20
SCHEMBL12205737	0.55	1/20
SCHEMBL13380054	0.55	1/20
SCHEMBL13380065	0.55	1/20
SCHEMBL13951109	0.55	1/20
SCHEMBL14209345	0.55	1/20
SCHEMBL13393702	0.55	1/20
SCHEMBL13393767	0.55	1/20
SCHEMBL8610946	0.54	1/20

Germline variants in MLX on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MLX gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MLX by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery	PHASE4	COMPLETED
A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia	PHASE3	COMPLETED
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis	PHASE3	COMPLETED
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors	PHASE2	UNKNOWN
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis	PHASE2	COMPLETED
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	PHASE1/PHASE2	SUSPENDED
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)	PHASE2	RECRUITING
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer	PHASE1/PHASE2	WITHDRAWN
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy	PHASE2	RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor	PHASE1	COMPLETED
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1	PHASE1	COMPLETED
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS	PHASE1	UNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Study of the Sex Differences in Inflammatory Diseases in Children	nan	UNKNOWN
A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Study of Selected X-Linked Disorders: Aicardi Syndrome	nan	RECRUITING
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing	nan	RECRUITING
Gene x Behavior Interaction in the Look AHEAD Study	nan	COMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project	nan	RECRUITING
Epidemiology of Atherosclerosis	nan	COMPLETED
Patient-derived Glioma Stem Cell Organoids	nan	ACTIVE_NOT_RECRUITING
Studying Chromosomes in Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Correlation Between PT and INR to Factor 7	nan	UNKNOWN
The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43	nan	UNKNOWN
Improvements in Aerobic Fitness With Exercise Training: the Role of Myokines	nan	COMPLETED
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a MLX binder may also engage these)

Protein	Name	Similarity
O08609	—	1.000	O08609 →
MORF4L1	Mortality factor 4-like protein 1	0.950	landscape →
APBA1	Amyloid-beta A4 precursor protein-binding fam	0.947	landscape →
P60762	—	0.946	P60762 →
Q6DN14	—	0.945	Q6DN14 →
P52161	—	0.943	P52161 →
E9PV86	—	0.941	E9PV86 →
Q6P5H6	—	0.941	Q6P5H6 →
Q6A039	—	0.941	Q6A039 →
M0R7T9	—	0.940	M0R7T9 →
X2JAU8	—	0.940	X2JAU8 →
Q64705	—	0.940	Q64705 →
Q15853	—	0.940	Q15853 →
B2RYF1	—	0.940	B2RYF1 →
B2RUJ5	—	0.940	B2RUJ5 →
Q63665	—	0.940	Q63665 →
Q8BKR5	—	0.939	Q8BKR5 →
O35430	—	0.939	O35430 →
Q5RD33	—	0.938	Q5RD33 →
A4IGK3	—	0.938	A4IGK3 →
P52162	—	0.937	P52162 →
Q96IK1	—	0.937	Q96IK1 →
Q5BJU6	—	0.936	Q5BJU6 →
P28574	—	0.936	P28574 →
Q642H2	—	0.936	Q642H2 →
D4ABL6	—	0.935	D4ABL6 →
O60347	—	0.935	O60347 →
Q8K4G5	—	0.935	Q8K4G5 →
Q5SQY2	—	0.934	Q5SQY2 →
P52164	—	0.934	P52164 →